Top Markets
Coin of the day
Skye Bioscience, Inc. Skye Bioscience, Inc.

Skye Bioscience, Inc.

SKYE
Rangering i aksjer #31353
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on... Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Aksjekurs
$0.4018
Markedsverdi
$14.12M
Endring (1 dag)
-3.20%
Endring (1 år)
-88.15%
Land
US
Handel Skye Bioscience, Inc. (SKYE)

Kategori

P/S-forhold for Skye Bioscience, Inc. (SKYE)
P/S-forhold per 2026 TTM: 0
Ifølge Skye Bioscience, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Skye Bioscience, Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
4.74 -
BE